Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Appili Therapeutics Inc (APLIF)

Appili Therapeutics Inc (APLIF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 48,883
  • Shares Outstanding, K 62,832
  • Annual Sales, $ 90 K
  • Annual Income, $ -10,860 K
  • 60-Month Beta -1.93
  • Price/Sales 529.13
  • Price/Cash Flow N/A
  • Price/Book 9.05
Trade APLIF with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6000 +29.67%
on 08/30/21
0.7846 -0.84%
on 09/10/21
+0.1709 (+28.15%)
since 08/27/21
3-Month
0.4804 +61.95%
on 07/15/21
0.7846 -0.84%
on 09/10/21
+0.1780 (+29.67%)
since 06/25/21
52-Week
0.4804 +61.95%
on 07/15/21
1.3000 -40.15%
on 02/17/21
-0.0820 (-9.53%)
since 09/25/20

Most Recent Stories

More News
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan(R)/Reeqonus(TM) for the Treatment of Mild-to-Moderate COVID-19

--Study expected to include patients with top priority COVID-19 variants, including Delta

APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan(R)/Reeqonus(TM) for COVID-19 Patients

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced it entered into an agreement...

APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan(R)/Reeqonus(TM) Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed patient...

APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced the results from its annual...

APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients

, /PRNewswire/ -- Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced that...

APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
Appili Therapeutics Appoints Veteran Healthcare Executive Rochelle Stenzler to its Board of Directors

Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, today announced the appointment of Rochelle...

REV : 10.44 (+0.48%)
APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS(TM) (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada's Interim Order

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's"), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response...

RDY : 64.66 (-0.32%)
APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
First Patient Dosed in Appili Therapeutics' Phase 3 Clinical Trial of Avigan(R) Tablets (Favipiravir) for the Treatment of COVID-19 in the United States

--Appili's broad COVID-19 clinical program focuses on the use of oral antivirals as an early intervention against the coronavirus in the outpatient setting

PRAH : 165.21 (-1.67%)
APLI.TO : 0.98 (+3.16%)
APLIF : 0.7780 (+3.79%)
OTC Markets Group Announces Quarterly Index Performance and Rebalancing

, /PRNewswire/ --  (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the third quarter 2020 performance and quarterly rebalancing of the OTCQX® and...

CORVF : 2.7550 (-4.82%)
ALLXF : 1.1000 (-3.51%)
CANSF : 0.4418 (-0.74%)
LONCF : 0.4770 (-4.37%)
MEDXF : 2.3900 (+1.27%)
UGDIF : 0.0813 (-1.09%)
ADRNY : 33.4720 (-0.94%)
KNTNF : 4.9001 (-0.20%)
PBTHF : 7.4500 (+1.64%)
DGOCF : 1.7300 (+1.76%)
ONVC : 2.1500 (-14.00%)
ALBY : 13.6000 (+0.74%)
ALPIB : 37.7000 (+0.27%)
BOID : 28.0000 (+4.67%)
DLMV : 8.8000 (-0.34%)
LBSI : 61.0000 (-7.58%)
LUMB : 12.6000 (unch)
OTTW : 14.7000 (+2.08%)
PBNC : 35.5500 (unch)
APLIF : 0.7780 (+3.79%)
BNCHF : 0.8900 (+11.14%)
HBORF : 0.8557 (-2.21%)
LUMIF : 0.4387 (+2.64%)
NSRXF : 7.0750 (+1.65%)
SDRLF : 0.2390 (+4.37%)
TAALF : 3.2500 (-0.98%)
TNYYF : 0.9099 (+4.04%)
TSCDY : 10.7000 (+0.19%)
TSKFF : 0.2120 (+1.29%)
FLOOF : 0.0915 (-0.11%)
KSHB : 0.6950 (+0.14%)
VSQTF : 0.3500 (-1.46%)
OTCM : 47.5000 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 0.8099
2nd Resistance Point 0.7958
1st Resistance Point 0.7869
Last Price 0.7780
1st Support Level 0.7639
2nd Support Level 0.7498
3rd Support Level 0.7409

See More

52-Week High 1.3000
Fibonacci 61.8% 0.9869
Fibonacci 50% 0.8902
Fibonacci 38.2% 0.7935
Last Price 0.7780
52-Week Low 0.4804

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar